Lierman E - Search Results

1

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J. Lierman E, et al. Blood. 2006 Aug 15;108(4):1374-6. doi: 10.1182/blood-2006-02-004457. Epub 2006 Apr 27. Blood. 2006. PMID: 16645167 Free PMC article.

2

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.

Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. Lierman E, et al. Haematologica. 2007 Jan;92(1):27-34. doi: 10.3324/haematol.10692. Haematologica. 2007. PMID: 17229632 Free article.

3

TV6 and PDGFRB: a license to fuse.

Lierman E, Cools J. Lierman E, et al. Haematologica. 2007 Feb;92(2):145-7. doi: 10.3324/haematol.11187. Haematologica. 2007. PMID: 17296561 Free article. No abstract available.

4

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P. Lierman E, et al. Leukemia. 2009 May;23(5):845-51. doi: 10.1038/leu.2009.2. Epub 2009 Feb 12. Leukemia. 2009. PMID: 19212337

5

Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.

Lierman E, Cools J. Lierman E, et al. Expert Rev Anticancer Ther. 2009 Sep;9(9):1295-304. doi: 10.1586/era.09.82. Expert Rev Anticancer Ther. 2009. PMID: 19761433 Review.

6

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen.

Lierman E, Van Miegroet H, Beullens E, Cools J. Lierman E, et al. Haematologica. 2009 Oct;94(10):1440-4. doi: 10.3324/haematol.2009.007328. Haematologica. 2009. PMID: 19794087 Free PMC article.

7

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

Wasag B, Lierman E, Meeus P, Cools J, Vandenberghe P. Wasag B, et al. Among authors: lierman e. Haematologica. 2011 Jun;96(6):922-6. doi: 10.3324/haematol.2010.036558. Epub 2011 Feb 17. Haematologica. 2011. PMID: 21330321 Free PMC article.

8

Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

Lierman E, Smits S, Cools J, Dewaele B, Debiec-Rychter M, Vandenberghe P. Lierman E, et al. Leukemia. 2012 Jul;26(7):1693-5. doi: 10.1038/leu.2012.8. Epub 2012 Jan 17. Leukemia. 2012. PMID: 22301675 Free article. No abstract available.

9

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.

Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Lierman E, et al. Blood. 2012 Aug 16;120(7):1529-31. doi: 10.1182/blood-2012-06-433821. Blood. 2012. PMID: 22899477 Free article. No abstract available.

10

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P. Sadovnik I, et al. Among authors: lierman e. Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6. Exp Hematol. 2014. PMID: 24407160 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters